Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aurobindo Pharma Limited (AUROPHARMA.NS)
INR1,550.20
-2.60 (-0.17%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Galaxy, Plot No. 1 500032
Hyderabad, TS, IN
Hyderabad, TS, IN
CEO
Kambam Nithyananda Reddy
Website
aurobindo.com
IPO
1996-01-15
ISIN INE406A01037
Also trades on
Bombay Stock Exchange · AUROPHARMA.BO (INR)
National Stock Exchange of India · AUROPHARMA.NS (INR)
Description
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR1,550.20
-2.60 (-0.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.04
Float Shares
278.94M
Free Float %
48.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.45% | -4.06% | +3.35% | +19.70% | +19.05% | +23.52% | +23.74% | +137.65% | +42.79% | +96.25% | +6,993.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,550.20
DCF (Unlevered)
4,709.47
+203.8%
DCF (Levered)
2,341.71
+51.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
72% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 15 | 0 |
| Hold | 4 | +3 |
| Sell | 2 | 0 |
| Strong Sell | 2 | 0 |
Quality scores
Altman Z-Score
3.63
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.1% Q1'26: +5.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+0.9% Q1'26: +1.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.7% ★ Q1'26: +17.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.1% ★ Q1'26: +14.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.9% ★ Q1'26: +10.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.18× ★ Q1'26: 1.12× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 25 Rev. Ana. 22 EPS Ana. |
Mar 2027 25 Rev. Ana. 24 EPS Ana. |
Mar 2028 26 Rev. Ana. 24 EPS Ana. |
Mar 2029 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
35.75B
est: 36.00B (-0.7%)
|
43.81B
est: 42.38B (+3.4%)
|
45.38B
est: 46.87B (-3.2%)
|
58.71B
est: 58.06B (+1.1%)
|
121.34B
est: 79.91B (+51.9%)
|
121.34B
est: 120.95B (+0.3%)
|
138.16B
est: 139.38B (-0.9%)
|
149.33B
est: 155.41B (-3.9%)
|
164.63B
est: 166.90B (-1.4%)
|
195.64B
est: 191.77B (+2.0%)
|
230.99B
est: 227.23B (+1.7%)
|
247.75B
est: 250.84B (-1.2%)
|
234.55B
est: 237.01B (-1.0%)
|
248.55B
est: 246.58B (+0.8%)
|
290.02B
est: 297.18B (-2.4%)
|
317.24B
est: 315.47B (+0.6%)
|
334.73B
324.21B – 337.66B
+6.1% YoY
|
387.14B
361.06B – 406.99B
+15.7% YoY
|
426.53B
384.91B – 473.45B
+10.2% YoY
|
465.75B
465.15B – 466.36B
+9.2% YoY
|
| EBITDA |
9.69B
est: -1.16B (+937.6%)
|
10.04B
est: 9.91B (+1.3%)
|
2.43B
est: 10.10B (-75.9%)
|
9.83B
est: -3.85B (+355.3%)
|
26.24B
est: 4.90B (+435.2%)
|
26.24B
est: 23.92B (+9.7%)
|
32.16B
est: 27.95B (+15.1%)
|
34.76B
est: 33.35B (+4.2%)
|
38.17B
est: 37.79B (+1.0%)
|
39.80B
est: 41.95B (-5.1%)
|
48.02B
est: 42.51B (+12.9%)
|
53.95B
est: 50.39B (+7.1%)
|
43.11B
est: 54.29B (-20.6%)
|
36.34B
est: 58.48B (-37.8%)
|
57.64B
est: 74.11B (-22.2%)
|
64.36B
est: 78.87B (-18.4%)
|
83.47B
80.85B – 84.20B
+5.8% YoY
|
96.54B
90.04B – 101.49B
+15.7% YoY
|
106.36B
95.98B – 118.06B
+10.2% YoY
|
116.14B
115.99B – 116.29B
+9.2% YoY
|
| EBIT |
8.20B
est: 4.91B (+67.1%)
|
8.33B
est: 7.99B (+4.1%)
|
428.40M
est: 8.72B (-95.1%)
|
7.38B
est: 1.09B (+574.0%)
|
22.95B
est: 8.81B (+160.4%)
|
22.95B
est: 28.13B (-18.4%)
|
28.26B
est: 26.64B (+6.1%)
|
30.51B
est: 30.66B (-0.5%)
|
32.62B
est: 32.44B (+0.6%)
|
33.12B
est: 36.47B (-9.2%)
|
39.40B
est: 38.34B (+2.8%)
|
44.54B
est: 43.42B (+2.6%)
|
33.06B
est: 46.78B (-29.3%)
|
25.12B
est: 50.39B (-50.2%)
|
43.92B
est: 55.67B (-21.1%)
|
49.87B
est: 58.80B (-15.2%)
|
62.70B
60.73B – 63.25B
+6.6% YoY
|
72.52B
67.63B – 76.23B
+15.7% YoY
|
79.90B
72.10B – 88.68B
+10.2% YoY
|
87.24B
87.13B – 87.36B
+9.2% YoY
|
| Net Income |
5.61B
est: 1.24B (+353.7%)
|
5.63B
est: 6.63B (-15.0%)
|
-1.24B
est: 6.22B (-119.9%)
|
2.94B
est: -1.53B (+292.1%)
|
15.76B
est: 4.05B (+289.6%)
|
15.76B
est: 18.07B (-12.8%)
|
20.25B
est: 18.43B (+9.9%)
|
23.02B
est: 22.17B (+3.8%)
|
24.23B
est: 24.72B (-2.0%)
|
23.65B
est: 27.22B (-13.1%)
|
28.45B
est: 28.20B (+0.9%)
|
53.35B
est: 31.45B (+69.6%)
|
26.48B
est: 33.89B (-21.8%)
|
19.28B
est: 19.78B (-2.5%)
|
31.73B
est: 35.21B (-9.9%)
|
34.86B
est: 33.91B (+2.8%)
|
35.05B
34.33B – 36.98B
+3.3% YoY
|
45.09B
36.69B – 49.46B
+28.6% YoY
|
52.44B
40.17B – 64.64B
+16.3% YoY
|
59.17B
56.12B – 61.77B
+12.8% YoY
|
| SGA |
3.10B
est: 6.93B (-55.3%)
|
1.98B
est: 7.29B (-72.8%)
|
2.96B
est: 8.27B (-64.2%)
|
11.18B
est: 13.43B (-16.8%)
|
13.55B
est: 20.89B (-35.1%)
|
13.55B
est: 28.60B (-52.6%)
|
16.02B
est: 38.11B (-58.0%)
|
18.45B
est: 40.13B (-54.0%)
|
22.41B
est: 44.97B (-50.2%)
|
27.39B
est: 56.15B (-51.2%)
|
33.33B
est: 67.12B (-50.3%)
|
36.58B
est: 78.87B (-53.6%)
|
35.75B
est: 84.98B (-57.9%)
|
36.56B
est: 91.53B (-60.1%)
|
40.43B
est: 48.95B (-17.4%)
|
45.47B
est: 52.09B (-12.7%)
|
55.13B
53.40B – 55.61B
+5.8% YoY
|
63.76B
59.47B – 67.03B
+15.7% YoY
|
70.25B
63.39B – 77.98B
+10.2% YoY
|
76.71B
76.61B – 76.81B
+9.2% YoY
|
| EPS |
10.41
est: 7.82 (+33.1%)
|
9.79
est: 9.64 (+1.6%)
|
-2.12
est: 5.38 (-139.4%)
|
5.05
est: 7.39 (-31.7%)
|
27.00
est: 20.06 (+34.6%)
|
27.00
est: 27.85 (-3.0%)
|
34.67
est: 35.02 (-1.0%)
|
39.33
est: 40.67 (-3.3%)
|
41.36
est: 43.33 (-4.5%)
|
40.36
est: 42.73 (-5.5%)
|
48.56
est: 45.96 (+5.7%)
|
91.05
est: 55.54 (+63.9%)
|
45.20
est: 45.92 (-1.6%)
|
32.90
est: 34.23 (-3.9%)
|
54.15
est: 60.10 (-9.9%)
|
59.81
est: 62.97 (-5.0%)
|
61.61
59.10 – 63.67
-2.2% YoY
|
76.83
63.16 – 85.16
+24.7% YoY
|
87.51
69.16 – 111.29
+13.9% YoY
|
101.84
96.62 – 106.34
+16.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
10.25B
OE per share TTM
17.62
Owner's Yield
1.21%
Maintenance CapEx ratio
16.90%
Maint CapEx / Avg PPE
46.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 24 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.05% | 124.8K | 0.07% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.04% | 5.42M | 0.06% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.04% | 2.29M | 0.17% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.04% | 2.29M | 0.17% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.04% | 1.13M | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.04% | 501.3K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.03% | 55.80M | 0.06% |
| 8 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.03% | 209.5K | 0.40% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.01% | 805.9K | 0.10% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.01% | 448.5K | 0.04% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.83M
Shares Outstanding
580.80M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mettu Madan Mohan Reddy | Whole-Time Director | 70M | male |
| Kambam Nityananda Reddy | Vice Chairman & MD | 55M | male |
| Santhanam Subramanian | Chief Financial Officer | 21M | male |
| Baddigam Adi Reddy | Compliance Officer & Company Secretary | 5M | male |
| Makkapati Satakarni | President of Biologics, Chief Executive Officer of Biologics, Vaccines and Peptid & Director | 800.0K | — |
| K. Suresh Kumar | Associate President of HR | — | — |
| Parveen Kumar Luthra | Chief Scientific Officer | — | — |
| S. Vijaya Kumar | President of Technical | — | — |
| Mula Surya Narayana Murthy | Senior Vice President of Accounts | — | male |
| Ilapakurty Chandra Rao | Senior Vice President of Admin | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AUROPHARMA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
